Cubillo A, et al. - Authors evaluated 71 patients with Eastern Cooperative Oncology Group 0-1 metastatic colorectal carcinoma (mCRC) to assess the association of angiogenic switch (AS) with clinical response during standard chemotherapy-bevacizumab treatment. They observed dynamic changes in candidates who were given chemotherapy plus bevacizumab, resulting in better disease control and longer progression-free survival (PFS). The median PFS of those with AS was 11.4 months vs 8.3 months for those without AS, supporting it as a potential marker of angiogenesis inhibitor effectiveness.